Allarity Therapeutics initiates phase II trial of Ixempra in Europe for the treatment of metastatic breast cancer
Allarity Therapeutics A/S announced that it has enrolled the first patient in its European Phase II clinical trial of Ixempra (ixabepilone) for the treatment of metastatic breast cancer.
